Murat Fani Bozkurt

After completing high school education at Denizli Anadolu Lisesi in 1991, Dr Bozkurt completed his medical training at Hacettepe University Medical School in 1997. He had his residency training at Department of Nuclear Medicine, Hacettepe University Faculty of Medicine between the years 1997and 2003. He began to work as an instructor at Department of Nuclear Medicine, Hacettepe University Faculty of Medicine in 2005.

Dr Bozkurt underwent a reseach fellowship program on oncological PET imaging at University of Pennsylvania PET Center in Philadelphia, USA in 2003.

Dr Bozkurt underwent a visiting scientist program on Cardiac PET imaging at Nuclear Cardiology Department at Harvard University Brigham and Women’s Hospital in 2009.

Dr Bozkurt had his associate professorship degree in 2010. He was also certified by European Board of Nuclear Medicine in the same year.

He was assigned as a member of Oncology Task Group of European Association of Nuclear Medicine (EANM) in 2010 and consequently functioned as senior advisor in the years 2014-2016. Dr Bozkurt undertook chief chair position for European Multimodality Imaging and Therapy (ESMIT) in the years 2016-2018.

He had his professorhip degree in Nuclear Medicine in the year 2019.

Dr Bozkurt was rewarded by Turkish Cancer Research Council in 2003 for the second best original research on oncology , for the third best oral presentation at IX. National Gynecologic Oncology Congress in the year 2004 and for the best international presentation awards in tehe years 2016 and 2017 at American Association of Nuclear Medicine Physicains (ACNM). He was invited for the first Young Investigator’s Meeting in the field of nuclear medicine therapy by European Association of Nuclear Medicine at Vienna in 2009 and he represented Turkey.

His areas of main interest are nuclear oncology diagnostic and therapeutic applications (especially Y-90 microsphere therapy for liver tumors), nuclear cardiology and intraoperative gamma probe applications in nuclear medicine.

1. Dose–Response and survival analysis after transarterial radioembolization for intrahepatic cholangiocarcinoma: A multicenter multicompartment dosimetry studySOYDAL Ç., ÖNEŞ T., BOZKURT M. F., IŞIK E. G., Selcuk N. A., COŞKUN N., et al.European Journal of Nuclear Medicine and Molecular Imaging, cilt.53, sa.11, ss.6559-6568, 2026 (SCI-Expanded, Scopus)
2. PET in myeloma redefined: a comparative imaging study with FDG and fluorocholine PET/CTKaya G., AKIN S., BÜYÜKAŞIK Y., BOZKURT M. F., TUNCEL M., Kiratli P. O.European Journal of Nuclear Medicine and Molecular Imaging, cilt.53, sa.4, ss.2325-2336, 2026 (SCI-Expanded, Scopus)
3. Inflammation and dosimetry in radioembolization: is C-reactive protein enough, or should we refine our biomarkers and dosimetric tools?Filippi L., BOZKURT M. F.Annals of Nuclear Medicine, 2026 (SCI-Expanded, Scopus)
4. MALT lymphoma with synchronous lacrimal gland and gastric involvement on 18F-FDG PET/CT: a rare presentationEryilmaz Y., Gezmis E., ÜNER A., AKIN S., BOZKURT M. F.Seminars in Nuclear Medicine, 2026 (SCI-Expanded, Scopus)
5. Clinical Role of PET/Computed Tomography in Body ImagingSoydaş-Turan B., Akin Losee M., BOZKURT M. F.Magnetic Resonance Imaging Clinics of North America, 2026 (SCI-Expanded, Scopus)
6. PET-CT in Esophageal, Gastric, and Colorectal MalignanciesMavi M. E., BOZKURT M. F.Magnetic Resonance Imaging Clinics of North America, 2026 (SCI-Expanded, Scopus)